CureVac Clocks Q1 Revenue Of $7.62M, Down By 71% YoY, Pre-tax Loss Was $(61.6)M
Portfolio Pulse from Benzinga Newsdesk
CureVac reported Q1 revenue of $7.62 million, a 71% decrease YoY, and a pre-tax loss of $61.6 million.
May 30, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CureVac's Q1 revenue declined by 71% YoY to $7.62 million, and the company reported a pre-tax loss of $61.6 million.
CureVac's significant decline in revenue and substantial pre-tax loss may negatively impact the stock price in the short term, as investors may perceive this as a sign of financial instability or underperformance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100